Prescribing information for the Exubera system recommends all patients have baseline spirometry testing, a follow-up 6 months after initiation of
treatment, and yearly follow-up thereafter. Exubera is not recommended for patients with baseline FEV1 or DLCO <70% predicted. In patients who experience a >20% decrease in FEV1, tests should be repeated. If this finding is confirmed, then treatment should be discontinued. Treatment should also be stopped in the rare case of acute bronchospasm (22).
Was this article helpful?
Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally